In my new article, (the 2nd in a series on Pharmaceutical & Biotech Lifecycle Management), I look at how early non-innovators are filing patents covering new drug products (very early) and some of the strategic ramifications. For those who like data – the article is accompanied by a couple of slides showing the data points.
I look forward to your thoughts.
(The first article in the series looked at whether generic products are being launched earlier than ever and some implications.)